This breakthrough was made possible by a new technology called Fertilo, developed by the American biotechnology company Gameto and implemented at the Santa Isabel clinic in Lima.
Fertilo represents an innovative approach to in vitro fertilization (IVF). Unlike the traditional method, where women undergo intensive hormonal stimulation to mature eggs, this new technology uses specially designed ovarian support cells. These cells replicate the natural egg maturation process in laboratory conditions, reducing the procedure’s duration to just three days and eliminating the need for 80% of hormonal injections.
The key advantage of Fertilo lies in minimizing the risks and side effects associated with hormonal therapy, including ovarian hyperstimulation syndrome. According to Luis Guzman, head of Pranor Labs & Science, who oversaw the IVF cycle using this technology, this achievement offers new opportunities for women who cannot or do not wish to undergo traditional IVF protocols.
Gameto has already received regulatory approval for the use of Fertilo in several countries, including Australia, Japan, Argentina, Paraguay, Mexico, and Peru, making the technology accessible to more patients worldwide.
